Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy
Z Jin, X Sun, Y Wang, C Zhou, H Yang… - Frontiers in …, 2022 - frontiersin.org
Immunotherapies, such as immune checkpoint inhibitors (ICIs) and chimeric antigen
receptor (CAR) T cells, have revolutionized the treatment of patients with advanced and …
receptor (CAR) T cells, have revolutionized the treatment of patients with advanced and …
Aggregation-induced emission luminogens for cell death research
Cell death is closely related to various diseases, and monitoring and controlling cell death is
a promising strategy to develop efficient therapy. Aggregation-induced emission luminogens …
a promising strategy to develop efficient therapy. Aggregation-induced emission luminogens …
T-cell engaging poly (lactic-co-glycolic acid) nanoparticles as a modular platform to induce a potent cytotoxic immunogenic response against PD-L1 overexpressing …
Bispecific nanoparticles (NPs) are conjugated with two antibodies that enhance T cell
cytotoxicity by sequentially targeting CD3 and tumor-specific proteins. This interaction …
cytotoxicity by sequentially targeting CD3 and tumor-specific proteins. This interaction …
Autophagy activation by dietary piceatannol enhances the efficacy of immunogenic chemotherapy
S Wang, G Wang, W Wu, Z Xu, J Yang, M Cao… - Frontiers in …, 2022 - frontiersin.org
Immunogenic cell death (ICD) promotes the immune antitumor response via releasing
damage-associated molecular patterns (DAMPs) from dying tumor cells. The induction of …
damage-associated molecular patterns (DAMPs) from dying tumor cells. The induction of …
Triggering immune system with nanomaterials for cancer immunotherapy
Q Li, Y Liu, Z Huang, Y Guo, Q Li - Frontiers in Bioengineering and …, 2022 - frontiersin.org
Cancer is a major cause of incidence rate and mortality worldwide. In recent years, cancer
immunotherapy has made great progress in the preclinical and clinical treatment of …
immunotherapy has made great progress in the preclinical and clinical treatment of …
Synergistic anti-tumor therapy by a homotypic cell membrane-cloaked biomimetic nanocarrier with exceptionally potent activity against hepatic carcinoma
S Feng, P Ni, Y Gong, B Geng, H Li, C Miao, R Fan… - Nano Research, 2022 - Springer
Hepatic carcinoma (HC) is the sixth most frequently occurring malignancies and the third
leading cause of cancer death worldwide. Sepantronium bromide (YM155) is a small …
leading cause of cancer death worldwide. Sepantronium bromide (YM155) is a small …
Identification of Immunogenic Cell Death-Related Signature for Glioma to Predict Survival and Response to Immunotherapy
Z Sun, H Jiang, T Yan, G Deng, Q Chen - Cancers, 2022 - mdpi.com
Simple Summary Glioma is a malignant primary brain tumor accounting for 75% of the total
cases. Notably, several immunotherapeutic and chemotherapeutic agents in glioma have …
cases. Notably, several immunotherapeutic and chemotherapeutic agents in glioma have …
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
J Le Naour, Z Sztupinszki, V Carbonnier… - …, 2022 - Taylor & Francis
The anticancer immune response is shaped by immunogenic cell stress and death
pathways. Thus, cancer cells can release danger-associated molecular patterns that act on …
pathways. Thus, cancer cells can release danger-associated molecular patterns that act on …